Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(14)60232-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Insights into Bioactive Peptides: Design, Synthesis, Structure-Activity Relationship.
Int J Mol Sci
December 2024
Institute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), Via Pietro Castellino 111, 80131 Naples, Italy.
In recent decades, peptides have attracted significant attention not only from Academia but also from big Pharma as novel potential therapeutic compounds [...
View Article and Find Full Text PDFNeuroinflammation in Alzheimer disease.
Nat Rev Immunol
December 2024
Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette/Belvaux, Luxembourg.
Article Synopsis
- Research highlights the significant role of immune processes in the development of Alzheimer's disease, which is the leading cause of dementia.
- Various studies indicate that both innate and adaptive immune responses contribute to the disease's pathology and are influenced by genetics and lifestyle factors.
- New therapeutic approaches targeting neuroinflammation are being explored in clinical settings, offering potential treatment options for Alzheimer's patients.
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
J Neurol Neurosurg Psychiatry
December 2024
Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories.
View Article and Find Full Text PDFEfficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.
Neuropsychopharmacol Rep
March 2025
Eisai Ltd., Hatfield, UK.
Article Synopsis
- The study aimed to investigate the effects of lemborexant (LEM) on individuals with insomnia who also experience mild depression or anxiety symptoms.
- Over a 12-month period, 61 subjects out of 949, who were using medications for depression/anxiety, were evaluated for changes in sleep quality and related measures while being treated with either LEM or a placebo.
- Results showed that while LEM was effective for improving sleep metrics in the subpopulation, the placebo response was stronger, resulting in a smaller effect size for LEM compared to the overall study population, but no new safety concerns were identified.
Research Integrity in Guidelines and evIDence synthesis (RIGID): a framework for assessing research integrity in guideline development and evidence synthesis.
EClinicalMedicine
August 2024
Department of Obstetrics and Gynaecology, Monash University, Victoria, Australia.
Background: Clinical guidelines rely on sound evidence to underpin recommendations for patient care. Compromised research integrity can erode public trust and the credibility of the scientific enterprise, with potential harm to patients. Despite increased recognition of integrity concerns in scientific literature, there are no processes or guidance for incorporating integrity assessments into evidence-based guideline development or evidence synthesis more broadly.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!